Antisense Therapeutics Ltd - ANP share price
About
Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. Its ATL1103 is in clinical development for acromegaly. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.
Company Profile
Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.
Price Summary
Price Chart
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Reports from Veye
Grab Your FREE Report on Top 5 ASX Stocks to Buy in 2026
Latest Article
